TOP TEN perturbations for 1553296_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553296_at
Selected probe(set): 1553296_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553296_at (1553296_at) across 6672 perturbations tested by GENEVESTIGATOR:

hepatocyte (ESC) / Hep-G2

Relative Expression (log2-ratio):7.3747597
Number of Samples:8 / 9
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control Hep-G2
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code:

keratinocyte differentiation study 2 (KLF4 siRNA) / keratinocyte differentiation study 2

Relative Expression (log2-ratio):6.0993137
Number of Samples:2 / 2
Experimental keratinocyte differentiation study 2 (KLF4 siRNA)
KLF4 (Kruppel-like factor 4) depleted primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. KLF4 depletion was done using siRNAs: KLF4i(A): CCGAGGAGTTCAACGATCT; KLF4i(B): TGACCAGGCACTACCGTAA. Differentiation was induced at 100% confluency.
Control keratinocyte differentiation study 2
Primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. Differentiation was induced at 100% confluency.

hepatocyte (ESC) / HepaRG

Relative Expression (log2-ratio):5.7635803
Number of Samples:8 / 12
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

colorectal cancer study 33 (adenocarcinoma; trans. colon) / normal transverse colon tissue

Relative Expression (log2-ratio):-3.961482
Number of Samples:5 / 2
Experimental colorectal cancer study 33 (adenocarcinoma; trans. colon)
Primary tumor samples derived from the transverse colon of patients with adenocarcinoma.
Control normal transverse colon tissue
Normal transverse colon tissue samples.

HCC study 3 (area B) / HCC study 3 (area C)

Relative Expression (log2-ratio):-3.9496574
Number of Samples:26 / 24
Experimental HCC study 3 (area B)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the periphery of the tumor (area B). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control HCC study 3 (area C)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken from the perilesional area of the tumor (area C). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.

HCC study 3 (area B) / non-tumor liver tissue

Relative Expression (log2-ratio):-3.9383793
Number of Samples:26 / 37
Experimental HCC study 3 (area B)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the periphery of the tumor (area B). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control non-tumor liver tissue
Histologically normal, healthy liver biopsy samples obtained from a clinically unaffected site from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous, non-malignant sample was taken from the unaffected edge of the liver (area E). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.

HCC study 9 (HBV; HCV) / normal liver tissue

Relative Expression (log2-ratio):-3.830803
Number of Samples:2 / 10
Experimental HCC study 9 (HBV; HCV)
Liver tissue biopsy sample from patients with Hepatitis B and C infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.

HCC study 3 (area A) / HCC study 3 (area C)

Relative Expression (log2-ratio):-3.8146334
Number of Samples:13 / 24
Experimental HCC study 3 (area A)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the center of the tumor (area A). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control HCC study 3 (area C)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken from the perilesional area of the tumor (area C). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.

HCC study 3 (area A) / non-tumor liver tissue

Relative Expression (log2-ratio):-3.8033552
Number of Samples:13 / 37
Experimental HCC study 3 (area A)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the center of the tumor (area A). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control non-tumor liver tissue
Histologically normal, healthy liver biopsy samples obtained from a clinically unaffected site from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous, non-malignant sample was taken from the unaffected edge of the liver (area E). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.

HCC study 3 (area B) / HCC study 3 (area D)

Relative Expression (log2-ratio):-3.7935152
Number of Samples:26 / 19
Experimental HCC study 3 (area B)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the periphery of the tumor (area B). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control HCC study 3 (area D)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken in an area 2-3 cm away from the tumor (area D). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.